Literature DB >> 29887448

PTEN induced putative kinase 1 (PINK1) alleviates angiotensin II-induced cardiac injury by ameliorating mitochondrial dysfunction.

Wenjun Xiong1, Jinghai Hua1, Zuheng Liu1, Wanqiang Cai1, Yujia Bai1, Qiong Zhan1, Wenyan Lai1, Qingchun Zeng1, Hao Ren2, Dingli Xu3.   

Abstract

BACKGROUND: Mitochondrial quality control is crucial to the development of angiotensin II (AngII)-induced cardiac hypertrophy. PTEN induced putative kinase 1 (PINK1) is rapidly degraded in normal mitochondria but accumulates in damaged mitochondria, triggering autophagy to protect cells. PINK1 mediates mitophagy in general, but whether PINK1 mediates AngII-induced mitophagy and the effects of PINK1 on AngII-induced injury are unknown. This study was designed to investigate the function of PINK1 in an AngII stimulation model and its regulation of AngII-induced mitophagy.
METHODS: We studied the function of PINK1 in mitochondrial homeostasis in AngII-stimulated cardiomyocytes via RNA interference-mediated knockdown and adenovirus-mediated overexpression of the PINK1 protein. Mitochondrial membrane potential (MMP), reactive oxygen species (ROS) production, adenosine triphosphate (ATP) content, cell apoptosis rates and cardiomyocyte hypertrophy were measured. The expression of LC3B, Beclin1 and p62 was measured. Mitochondrial morphology was examined via electron microscopy. Mitophagy was detected by confocal microscopy based on the co-localization of lysosomes and mitochondria. Additionally, endogenous PINK1, phosphorylated PINK1, mito-PINK1, total Parkin, cyto-Parkin, mito-Parkin and phosphorylated Parkin protein levels were measured.
RESULTS: Cardiomyocytes untreated by AngII had very low levels of total and phosphorylated PINK1. However, in the AngII stimulation model, the MMP was decreased, and the levels of total and phosphorylated PINK1 were increased. After PINK1 was knocked down, Parkin translocation to the mitochondria was inhibited. Moreover, levels of phosphorylated Parkin were reduced, and autophagy markers were downregulated. MMP and ATP contents were further reduced, ROS production and the apoptotic rate were further increased, and myocardial hypertrophy was further aggravated compared with those in the AngII group. However, PINK1 overexpression promoted Parkin translocation and phosphorylation, autophagy markers were upregulated, and myocardial injury was reduced. In addition, the effects of PINK1 overexpression were reversed by autophagy inhibitors.
CONCLUSION: Decreased MMP induced by AngII maintains the stability of PINK1, causing PINK1 autophosphorylation. PINK1 activation promotes Parkin translocation and phosphorylation and increases autophagy to clear damaged mitochondria. Thus, PINK1/Parkin-mediated mitophagy has a compensatory, protective role in AngII-induced cytotoxicity.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Angiotensin II; MMP; Mitophagy; PINK1; Parkin

Mesh:

Substances:

Year:  2018        PMID: 29887448     DOI: 10.1016/j.ijcard.2018.03.054

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

1.  Mitofusin 2 Participates in Mitophagy and Mitochondrial Fusion Against Angiotensin II-Induced Cardiomyocyte Injury.

Authors:  Wenjun Xiong; Zhuang Ma; Dongqi An; Zuheng Liu; Wanqiang Cai; Yujia Bai; Qiong Zhan; Wenyan Lai; Qingchun Zeng; Hao Ren; Dingli Xu
Journal:  Front Physiol       Date:  2019-04-10       Impact factor: 4.566

2.  Stimulation of Na+/K+-ATPase with an Antibody against Its 4th Extracellular Region Attenuates Angiotensin II-Induced H9c2 Cardiomyocyte Hypertrophy via an AMPK/SIRT3/PPARγ Signaling Pathway.

Authors:  Siping Xiong; Hai-Jian Sun; Lei Cao; Mengyuan Zhu; Tengteng Liu; Zhiyuan Wu; Jin-Song Bian
Journal:  Oxid Med Cell Longev       Date:  2019-09-15       Impact factor: 6.543

3.  UCP2 silencing aggravates mitochondrial dysfunction in astrocytes under septic conditions.

Authors:  Wanwan Peng; Jinda Huang; Yijun Zheng; Yue Ding; Sitao Li; Junliang Zhang; Juanjuan Lyu; Qiyi Zeng
Journal:  Mol Med Rep       Date:  2019-10-02       Impact factor: 2.952

Review 4.  Mitophagy in Hepatic Insulin Resistance: Therapeutic Potential and Concerns.

Authors:  Zuqing Su; Yutong Nie; Xiufang Huang; Ying Zhu; Bing Feng; Lipeng Tang; Guangjuan Zheng
Journal:  Front Pharmacol       Date:  2019-10-10       Impact factor: 5.810

5.  Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.

Authors:  Dan Zhang; Xiuying Chen; Hexia Xia; Lu Wang; Hongbo Zhao; Bufang Xu; Aijun Zhang; Wei Zhang
Journal:  BMC Cancer       Date:  2020-09-03       Impact factor: 4.430

Review 6.  FUNDC1: A Promising Mitophagy Regulator at the Mitochondria-Associated Membrane for Cardiovascular Diseases.

Authors:  Guoyong Li; Junli Li; Ruochen Shao; Jiahao Zhao; Mao Chen
Journal:  Front Cell Dev Biol       Date:  2021-12-16

7.  Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes.

Authors:  Bing-Yan Liu; Ling Li; Gao-Li Liu; Wei Ding; Wen-Guang Chang; Tao Xu; Xiao-Yu Ji; Xian-Xin Zheng; Jing Zhang; Jian-Xun Wang
Journal:  Acta Pharmacol Sin       Date:  2020-08-14       Impact factor: 6.150

8.  Mitophagy in Hypertension-Associated Premature Vascular Aging.

Authors:  Zachary J Schreckenberger; Camilla F Wenceslau; Bina Joe; Cameron G McCarthy
Journal:  Am J Hypertens       Date:  2020-09-10       Impact factor: 2.689

Review 9.  Mitochondrial Quality Control in Cardiomyocytes: A Critical Role in the Progression of Cardiovascular Diseases.

Authors:  Hualin Fan; Zhengjie He; Haofeng Huang; Haixia Zhuang; Hao Liu; Xiao Liu; Sijun Yang; Pengcheng He; Huan Yang; Du Feng
Journal:  Front Physiol       Date:  2020-03-27       Impact factor: 4.566

10.  STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways.

Authors:  Fei Liu; Hao Su; Bo Liu; Ying Mei; Qingjin Ke; Xiaoou Sun; Wen Tan
Journal:  Int J Mol Sci       Date:  2020-01-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.